Eli Lilly’s big-selling insulin ... acting insulin market with a cheaper version of Sanofi’s Lantus (insulin glargine). Approved at the beginning of 2016, US revenues of the cheaper competitor ...

The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro) by 2024.

Notably, GLP-1 drugs help regulate blood sugar, insulin levels, and appetite, mainly treating type 2 diabetes and, more recently, obesity. Eli Lilly currently markets two GLP-1 receptor agonist ...

The weight loss drug market could grow to $500 billion over the next decade. Eli Lilly's next-generation products look promising, while competitors have stumbled in clinical trials. Investors are ...

Eli Lilly's oral GLP-1 medicine aced a phase 3 study. It should become a new growth driver for the company. There are other reasons to invest in the pharmaceutical leader. Zepbound's prospects ...

Pharmaceutical giant Eli Lilly and Co. sued Willow Health Services and three other companies in federal court in New Jersey and California, accusing them of selling unapproved compounded ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...

Eli Lilly's Orforglipron shows promising Phase III results, potentially becoming a best-in-class oral GLP-1 receptor agonist for diabetes and obesity by 2026. Despite macroeconomic headwinds ...

Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss medications. Lilly filed four lawsuits on Wednesday claiming telehealth ...

April 23 (UPI) --Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling compounds of slightly-different versions of Lilly drugs.

Given the potential opportunities in the sector, should investors buy Eli Lilly stock? Here's where the company and its stock stand now. The GLP-1 agonist opportunity is gearing up for its next ...